These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8303660)

  • 21. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
    Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
    Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased plasma fibrinolytic activity in bleeding gastrointestinal angiodysplasia.
    Junquera F; Saperas E; Anglés A; Abadía C; Monasterio J; Malagelada JR
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):199-205. PubMed ID: 15674098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in fibrinolysis-associated parameters in HELLP syndrome].
    Kolben M; Lopens A; Schmitt M; Schneider KT; Graeff H
    Geburtshilfe Frauenheilkd; 1994 May; 54(5):257-61. PubMed ID: 8050684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
    Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
    Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
    Salat C; Boekstegers P; Holler E; Werdan K; Reinhardt B; Fateh-Moghadam S; Pihusch R; Kaul M; Beinert T; Hiller E
    Shock; 1996 Oct; 6(4):233-7. PubMed ID: 8902937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.
    Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM
    J Clin Invest; 1998 Sep; 102(5):919-28. PubMed ID: 9727060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired fibrinolysis and insulin resistance in patients with hypertension.
    Jeng JR; Sheu WH; Jeng CY; Huang SH; Shieh SM
    Am J Hypertens; 1996 May; 9(5):484-90. PubMed ID: 8735180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Plasminogen System and Transforming Growth Factor-β in Subjects With Obstructive Sleep Apnea Syndrome: Effects of CPAP Treatment.
    Steffanina A; Proietti L; Antonaglia C; Palange P; Angelici E; Canipari R
    Respir Care; 2015 Nov; 60(11):1643-51. PubMed ID: 26286733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
    Strauss BH; Lau HK; Bowman KA; Sparkes J; Chisholm RJ; Garvey MB; Fenkell LL; Natarajan MK; Singh I; Teitel JM
    Circulation; 1999 Oct; 100(15):1616-22. PubMed ID: 10517732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
    Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the plasminogen activator system in the human vascular wall.
    Salame MY; Samani NJ; Masood I; deBono DP
    Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
    Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
    Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
    Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
    Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy.
    Uszyński M; Maciejewski K; Uszyński W; Kuczyński J
    Gynecol Obstet Invest; 2001; 52(3):189-93. PubMed ID: 11598362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.